ArticleCardiovascular research2026
Lgi3-4 proteins modulate the KV1.5 channelosome and are potential therapeutic targets for atrial fibrillation.
Article in Cardiovascular research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Selective inhibition of LY294002 across cloned human cardiac ion channels: implications for atrium-selective therapy in atrial fibrillation.Frontiers in pharmacology · 2026Article
Corrections and comments
- Commented on by
Authors and funding
16 authors.
Funding
Abstract
aimsWe investigated the role of Lgi3-4 proteins in cardiac electrophysiology, with a specific focus on IKur, and their potential contribution to the pathophysiology of atrial fibrillation (AF). METHODS AND
resultsIn human atrial tissue and heterologous cells, Lgi3 and Lgi4 interacted with KV1.5 channels. In a mouse model of AAV9-mediated cardiac-specific Lgi4 expression, sinoatrial and atrioventricular conduction were impaired, resulting in a prolonged QRS interval. Action potential repolarisation was delayed in atrial and ventricular cardiomyocytes from Lgi4 mice. In HEK293 cells, Lgi3-4 impaired KV1.5/KVβ association, partially reversing the KVβ-induced inactivation and reducing IKur amplitude. These results correlated with the reduced KV1.5 membrane expression and IKur density observed in Lgi4 cardiomyocytes and HEK293 cells. Notably, Lgi4 protein expression was lower in atrial tissue from patients with AF than in sinus rhythm patients. The reduced Lgi4 protein levels in AF were also associated with an altered colocalisation with KV1.5 channels, suggesting potential disruption in their functional interactions.
conclusionWe conclude that Lgi3-4 proteins are new components of the cardiac KV1.5 channelosome. They modulate IKur by interfering with the KV1.5-KVβ interaction. Significantly, Lgi4 is dysregulated differently in paroxysmal vs. permanent AF. The results identify Lgi3-4 proteins as novel regulators of the KV1.5 channelosome, opening new pathways for investigating the role of IKur dysfunction in the mechanism of atrial fibrillation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.